Evidence map›Paper›PMID 41024979›Full record

ReviewWorld journal of gastrointestinal pathophysiology2025

CRISPR/Cas9 gene editing in gastric cancer: Mechanisms, advances, and therapeutic potential.

Grigorios Christodoulidis, Dimitra Bartzi, Kyriaki Tsagkidou, Alexandra Dimaki, Lydia Lazaridou, Kalliopi Vakalou, Konstantinos E Koumarelas, Dimitrios Schizas

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastrointestinal pathophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Grigorios ChristodoulidisDepartment of General Surgery, University Hospital of Larissa, Larissa 41110, Thessalia, Greece. gregsurg@yahoo.gr.
Dimitra BartziDepartment of Oncology, The 251 Airforce General Hospital, Athens 11525, Greece.
Kyriaki TsagkidouDepartment of Gastroenterology, University Hospital of Larisa, Larisa 41100, Thessalia, Greece.
Alexandra DimakiDepartment of General Surgery, University Hospital of Larissa, Larissa 41110, Thessalia, Greece.
Lydia LazaridouDepartment of General Surgery, University Hospital of Larissa, Larissa 41110, Thessalia, Greece.
Kalliopi VakalouDepartment of General Surgery, University Hospital of Larissa, Larissa 41110, Thessalia, Greece.
Konstantinos E KoumarelasDepartment of General and Orthopaedic Surgery, Luzerner Kantonsspital Wolhusen, Luzern 6110, Switzerland.
Dimitrios SchizasDepartment of First Surgery, National and Kapodistrian University of Athens, Athens 11527, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) remains one of the leading causes of cancer-related mortality worldwide, necessitating innovative approaches for its diagnosis and treatment. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a revolutionary gene-editing technology, has emerged as a powerful tool for unraveling the molecular mechanisms underlying GC and for advancing precision medicine strategies. This review explores the current applications of CRISPR/Cas9 in GC research, including the identification of oncogenes and tumor suppressors, modeling tumor microenvironment interactions, and developing gene-based therapies. We highlight recent breakthroughs in genome editing that have enhanced our understanding of GC pathogenesis and resistance mechanisms to conventional therapies. Additionally, we discuss the potential of CRISPR/Cas9 for therapeutic gene editing in GC, addressing challenges such as off-target effects, delivery methods, and ethical considerations. By summarizing the progress and limitations of CRISPR/Cas9 in GC, this review aims to provide a comprehensive perspective on how this transformative technology could shape future strategies for the prevention, diagnosis, and treatment of GC.

Indexed as

Clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeats-associated protein 9Gastric cancerGene-editing technologiesHelicobacter pyloriPrecision genome editing

Identifiers

PMID41024979
PMCPMC12476675

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.